When both mutations are present, the NPM1 mutation supersedes the BCR: ABL1 and is considered as a favorable risk category (ELN 2022 does not specifically comments on this category, in contrast to AML with BCR: ABL1 with NPM1wt which is considered as adverse risk). The gene discussed is ABL1; the disease is acute myeloid leukemia.